Thymectomy lowers the myasthenia gravis biomarker miR-150-5p
Citation Manager Formats
Make Comment
See Comments

Abstract
Objective The aim of the study was to analyze the effect of thymectomy on the proposed disease-specific microRNA (miRNA) biomarkers miR-150-5p and miR-21-5p in patients from the prospective randomized trial of thymectomy in myasthenia gravis (MGTX trial) and to evaluate the longitudinal changes in clinical patterns compared with these miRNA levels.
Methods Serum samples were obtained from 80 patients with MG who were included in the MGTX trial. Thirty-eight patients were randomized to thymectomy plus prednisone treatment, and 42 patients were randomized to prednisone treatment. Serum samples were analyzed for the expression of miR-150-5p and miR-21-5p, with quantitative reverse transcriptase PCR at baseline and at 12, 24, and 36 months after randomization. The inclusion criteria for participation in the MGTX trial were age 18–65 years, generalized myasthenia gravis (Myasthenia Gravis Foundation of America Class II–IV), disease duration of less than 5 years, and seropositivity for acetylcholine receptor antibodies (AChR+).
Results Patients treated with thymectomy had lower levels of miR-150-5p at 24 months, both compared with baseline values (p = 0.0011) and the prednisone group (p = 0.04). No change in miRNA levels was found in the prednisone group. Levels of miR-21-5p displayed a negative correlation with the prednisone dose within the prednisone-only group (p ≤ 0.001).
Conclusions Thymectomy lowers the levels of the proposed biomarker miR-150-5p, which strengthens its position as a potential disease-specific biomarker for AChR+ MG.
Glossary
- AChR=
- acetylcholine receptor;
- ANCOVA=
- analysis of covariance;
- cDNA=
- complementary DNA;
- EOMG=
- early-onset myasthenia gravis;
- EV=
- extracellular vesicle;
- LPF=
- low-power field;
- miRNA=
- microRNA;
- MG=
- myasthenia gravis;
- MGTX trial=
- randomized trial of thymectomy in myasthenia gravis;
- qPCR=
- quantitative PCR;
- QMG=
- quantitative MG;
- TFH=
- thymic lymphofollicular hyperplasia
Footnotes
Funding information and disclosures are provided at the end of the article. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NN.
The Article Processing Charge was funded by the authors.
- Received October 27, 2017.
- Accepted in final form January 30, 2018.
- Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Views & Reviews
International Consensus Guidance for Management of Myasthenia Gravis2020 UpdatePushpa Narayanaswami, Donald B. Sanders, Gil Wolfe et al.Neurology, November 03, 2020 -
Article
Minimal manifestation status and prednisone withdrawal in the MGTX trialIkjae Lee, Hui-Chien Kuo, Inmaculada B. Aban et al.Neurology, July 01, 2020 -
Special Article
Practice advisory: Thymectomy for myasthenia gravis (practice parameter update)Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of NeurologyGary S. Gronseth, Richard Barohn, Pushpa Narayanaswami et al.Neurology, March 25, 2020 -
Article
IV immunoglobulin in patients with myasthenia gravisA randomized controlled trialLorne Zinman, Eduardo Ng, Vera Bril et al.Neurology, March 12, 2007